News|Articles|February 14, 2025
NeurologyLive® Friday 5 — February 14, 2024
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 14, 2024.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Addressing Social Isolation in Narcolepsy and Idiopathic Hypersomnia: Julie Flygare, JD
The president and CEO at Project Sleep highlighted the need for clinicians to facilitate awareness of patient advocacy resources for those living with narcolepsy or idiopathic hypersomnia. [WATCH TIME: 5 minutes]
2: Safety Considerations and Personalizing SPN-830 Treatment for Parkinson Disease: Stuart Isaacson, MD, FAAN
The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, commented on the promising safety of SPN-830 and who may be best suited for treatment with the newly approved therapy. [WATCH TIME: 4 minutes]
3: Expanding the Time Window for Intravenous Thrombolysis in Ischemic Stroke: Min Lou MD, PhD
The professor at the Second Affiliated Hospital of Zhejiang University’s School of Medicine discussed findings from a trial suggesting that intravenous thrombolysis could benefit patients with ischemic stroke up to 24 hours after symptom onset. [WATCH TIME: 8 minutes]
4: NeuroVoices: Véronique Miron, PhD, on Exciting Developments and Expectations for ACTRIMS 2025
The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.
5: Advancing Clinical Trials and Treatment Strategies for Charcot-Marie-Tooth Disease: Joshua Burns, PhD
The clinical researcher at St. Jude Children's Research Hospital discussed the evolving treatment landscape for Charcot-Marie-Tooth disease, which will be featured in a session at the 2025 MDA Conference. [WATCH TIME: 7 minutes]
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
3
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
4
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
5